z-logo
open-access-imgOpen Access
Association of T315I mutation with resistance to tyrosine kinase inhibitor therapy in patients with CML attended the Oncology-Hematology center in Al-Najaf city of Iraq
Author(s) -
Rahem Mahdy Rahem,
Adel Abdulhussien Abuhmood,
Luwaa Hussein
Publication year - 2017
Publication title -
karbala international journal of modern science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.345
H-Index - 17
eISSN - 2405-6103
pISSN - 2405-609X
DOI - 10.1016/j.kijoms.2017.08.004
Subject(s) - medicine , dasatinib , imatinib , hematology , guideline , nilotinib , tyrosine kinase , oncology , myeloid leukemia , pathology , receptor

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom